Identification

Name
Candoxatril
Accession Number
DB00616  (APRD00027)
Type
Small Molecule
Groups
Experimental
Description

Candoxatril is the orally-active prodrug of candoxatrilat (UK-73967), a potent neutral endopeptidase (NEP) inhibitor.

Structure
Thumb
Synonyms
  • [4(S)-cis]-4-[[[1-[3-[(2,3-dihydro-1H-Indeb5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic acid
  • 4-({1-[(S)-2-(indan-5-yloxycarbonyl)-3-(2-methoxy-ethoxy)-propyl]-cyclopentanecarbonyl}-amino)-cyclohexanecarboxylic acid
External IDs
UK-79,300 / UK-79300
Categories
UNII
ACP75508EE
CAS number
123122-55-4
Weight
Average: 515.6383
Monoisotopic: 515.288302671
Chemical Formula
C29H41NO7
InChI Key
ZTWZVMIYIIVABD-OEMFJLHTSA-N
InChI
InChI=1S/C29H41NO7/c1-35-15-16-36-19-23(27(33)37-25-12-9-20-5-4-6-22(20)17-25)18-29(13-2-3-14-29)28(34)30-24-10-7-21(8-11-24)26(31)32/h9,12,17,21,23-24H,2-8,10-11,13-16,18-19H2,1H3,(H,30,34)(H,31,32)/t21-,23-,24+/m0/s1
IUPAC Name
(1s,4s)-4-{1-[(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentaneamido}cyclohexane-1-carboxylic acid
SMILES
COCCOC[C@H](CC1(CCCC1)C(=O)N[C@H]1CC[C@H](CC1)C(O)=O)C(=O)OC1=CC2=C(CCC2)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Neutral endopeptidase inhibitors such as Candoxatril have a dual mechanism of action. They inhibit two metalloprotease enzymes, neutral endopeptidase and ACE, resulting in an increased availability of natriuretic peptides that exhibit vasodilatory effects and, possibly, tissue protective effects.

TargetActionsOrganism
ANeprilysin
inhibitor
Human
UAngiotensin-converting enzyme
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Candoxatril.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Candoxatril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Candoxatril.Approved, Investigational
AcebutololCandoxatril may increase the hypotensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Candoxatril.Approved, Investigational
AcemetacinThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Candoxatril.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Candoxatril.Approved, Withdrawn
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Candoxatril.Approved, Investigational
AliskirenAliskiren may increase the hypotensive, nephrotoxic, and hyperkalemic activities of Candoxatril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Candoxatril.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Candoxatril.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Candoxatril.Approved
AloxiprinThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Aloxiprin.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Candoxatril.Approved, Illicit, Investigational
AlprenololCandoxatril may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanCandoxatril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Candoxatril.Experimental, Investigational
AmifostineCandoxatril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hyperkalemic activities of Candoxatril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Candoxatril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Candoxatril.Approved
Aminosalicylic AcidThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Aminosalicylic Acid.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Candoxatril.Approved
AmitriptylinoxideThe serum concentration of Amitriptylinoxide can be increased when it is combined with Candoxatril.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Candoxatril.Approved
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Candoxatril.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Candoxatril.Approved, Illicit, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Candoxatril.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Candoxatril.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Candoxatril.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Candoxatril.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Candoxatril.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Candoxatril.Approved, Investigational, Withdrawn
AtenololAtenolol may increase the hypotensive activities of Candoxatril.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Candoxatril.Approved
AvanafilAvanafil may increase the antihypertensive activities of Candoxatril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Candoxatril.Withdrawn
AzathioprineThe risk or severity of anemia and severe leukopenia can be increased when Candoxatril is combined with Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Candoxatril.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Candoxatril.Approved, Investigational
AzosemideAzosemide may increase the hypotensive activities of Candoxatril.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Candoxatril.Approved, Investigational
BarnidipineCandoxatril may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Candoxatril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Candoxatril.Experimental
BendroflumethiazideThe risk or severity of hypotension can be increased when Bendroflumethiazide is combined with Candoxatril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Candoxatril.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Candoxatril.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Candoxatril.Withdrawn
BenzthiazideThe risk or severity of hypotension can be increased when Benzthiazide is combined with Candoxatril.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Candoxatril.Approved
BepridilCandoxatril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Candoxatril.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Candoxatril.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Candoxatril.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Candoxatril.Experimental
BimatoprostCandoxatril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Candoxatril.Approved
BoceprevirThe serum concentration of Candoxatril can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BosentanBosentan may increase the hypotensive activities of Candoxatril.Approved, Investigational
BQ-123Candoxatril may increase the hypotensive activities of BQ-123.Investigational
BretyliumCandoxatril may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Candoxatril.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Candoxatril.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Candoxatril.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Candoxatril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Candoxatril.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Candoxatril.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Candoxatril.Experimental
BumetanideBumetanide may increase the hypotensive activities of Candoxatril.Approved
BupranololCandoxatril may increase the hypotensive activities of Bupranolol.Approved
ButriptylineThe serum concentration of Butriptyline can be increased when it is combined with Candoxatril.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Candoxatril.Approved
CadralazineCadralazine may increase the hypotensive activities of Candoxatril.Experimental
CafedrineCandoxatril may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Candoxatril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Candoxatril.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Candoxatril.Approved
CaptoprilCandoxatril may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Candoxatril can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Candoxatril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Candoxatril.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Candoxatril.Approved
CarvedilolCandoxatril may increase the hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Candoxatril.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Candoxatril.Approved, Investigational
CeliprololCandoxatril may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Candoxatril.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of hypotension can be increased when Chlorothiazide is combined with Candoxatril.Approved, Vet Approved
ChlorthalidoneThe risk or severity of hypotension can be increased when Chlorthalidone is combined with Candoxatril.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Candoxatril.Approved
CicletanineCandoxatril may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCandoxatril may increase the hypotensive activities of Cilazapril.Approved
CiprofloxacinThe risk or severity of ventricular arrhythmias can be increased when Candoxatril is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Candoxatril.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Candoxatril.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Candoxatril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Candoxatril.Approved
CloranololCandoxatril may increase the hypotensive activities of Cloranolol.Experimental
CryptenamineCandoxatril may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Candoxatril.Approved, Investigational
CyclopenthiazideThe risk or severity of hypotension can be increased when Cyclopenthiazide is combined with Candoxatril.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Candoxatril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Candoxatril.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Candoxatril.Approved
DapagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Candoxatril.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Candoxatril.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Candoxatril.Approved, Investigational
DelaprilCandoxatril may increase the hypotensive activities of Delapril.Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Candoxatril.Approved
DersalazineThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Dersalazine.Investigational
DeserpidineCandoxatril may increase the hypotensive activities of Deserpidine.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Candoxatril.Approved, Investigational
DiazoxideDiazoxide may increase the hypotensive activities of Candoxatril.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Candoxatril.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Candoxatril.Approved, Vet Approved
DiethylnorspermineCandoxatril may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Candoxatril.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Candoxatril.Experimental
DiflunisalThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Diflunisal.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Candoxatril.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Candoxatril.Approved, Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Candoxatril.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Candoxatril.Approved, Investigational
DimetacrineThe serum concentration of Dimetacrine can be increased when it is combined with Candoxatril.Approved, Withdrawn
DipyridamoleDipyridamole may increase the antihypertensive activities of Candoxatril.Approved
DorzolamideCandoxatril may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Candoxatril.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Candoxatril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Candoxatril.Approved, Investigational
DrospirenoneCandoxatril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Candoxatril.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Candoxatril.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Candoxatril.Approved
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Candoxatril.Investigational
EfonidipineCandoxatril may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Empagliflozin is combined with Candoxatril.Approved
EnalaprilEnalapril may increase the hypotensive activities of Candoxatril.Approved, Vet Approved
EnalaprilatCandoxatril may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Candoxatril.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Candoxatril.Approved, Investigational
EpanololCandoxatril may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Candoxatril.Approved
EpitizideThe risk or severity of hypotension can be increased when Epitizide is combined with Candoxatril.Experimental
EplerenoneEplerenone may increase the hyperkalemic activities of Candoxatril.Approved
EpoprostenolCandoxatril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Candoxatril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Candoxatril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Candoxatril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Candoxatril.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Candoxatril.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with Candoxatril.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with Candoxatril.Approved, Investigational, Vet Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Candoxatril.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Candoxatril.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Candoxatril.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Candoxatril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Candoxatril.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Candoxatril.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Candoxatril.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Candoxatril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Candoxatril.Investigational, Nutraceutical
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Candoxatril.Approved
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Candoxatril.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Candoxatril.Experimental
FelodipineCandoxatril may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Candoxatril.Approved
FenoldopamCandoxatril may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Candoxatril.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Candoxatril.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Candoxatril.Experimental
Ferulic acidCandoxatril may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Candoxatril.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Candoxatril.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Candoxatril.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Candoxatril.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Candoxatril.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Candoxatril.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Candoxatril.Approved
FostamatinibFostamatinib may increase the antihypertensive activities of Candoxatril.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Candoxatril.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Candoxatril.Approved, Vet Approved
GarlicThe serum concentration of Candoxatril can be decreased when it is combined with Garlic.Approved, Nutraceutical
GuacetisalThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Guacetisal.Experimental
GuanabenzCandoxatril may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Candoxatril.Approved
GuanazodineCandoxatril may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineCandoxatril may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Candoxatril.Approved, Investigational
GuanoclorCandoxatril may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzCandoxatril may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanCandoxatril may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Candoxatril.Experimental
Hemoglobin crosfumarilThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
HeparinThe risk or severity of hyperkalemia can be increased when Candoxatril is combined with Heparin.Approved, Investigational
HexamethoniumCandoxatril may increase the hypotensive activities of Hexamethonium.Experimental
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Candoxatril.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Candoxatril.Experimental
HydralazineHydralazine may increase the hypotensive activities of Candoxatril.Approved
HydrochlorothiazideThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Candoxatril.Approved, Vet Approved
HydroflumethiazideThe risk or severity of hypotension can be increased when Hydroflumethiazide is combined with Candoxatril.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Candoxatril.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Candoxatril.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Candoxatril.Approved, Investigational
IloprostIloprost may increase the hypotensive activities of Candoxatril.Approved, Investigational
ImidaprilCandoxatril may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Candoxatril.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Candoxatril.Approved
IndapamideThe risk or severity of hypotension can be increased when Indapamide is combined with Candoxatril.Approved
IndenololCandoxatril may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Candoxatril.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Candoxatril.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Candoxatril.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Candoxatril.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Candoxatril.Experimental
IproclozideIproclozide may increase the hypotensive activities of Candoxatril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Candoxatril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Candoxatril.Approved, Investigational
IronIron can cause a decrease in the absorption of Candoxatril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Candoxatril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Candoxatril.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Candoxatril.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Candoxatril.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Candoxatril.Experimental
KetanserinKetanserin may increase the hypotensive activities of Candoxatril.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Candoxatril.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Candoxatril.Approved
LabetalolLabetalol may increase the hypotensive activities of Candoxatril.Approved
LacidipineCandoxatril may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Candoxatril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostCandoxatril may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Candoxatril.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Candoxatril.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Candoxatril.Approved
LinsidomineCandoxatril may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilCandoxatril may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Candoxatril.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Candoxatril.Experimental
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Candoxatril.Experimental
LofexidineCandoxatril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Candoxatril.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Candoxatril.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Candoxatril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Candoxatril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Candoxatril.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Candoxatril.Approved, Investigational
MacitentanCandoxatril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Candoxatril.Approved
ManidipineCandoxatril may increase the hypotensive activities of Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Candoxatril.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Candoxatril.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Candoxatril.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Candoxatril.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Candoxatril.Approved
MelitracenThe serum concentration of Melitracen can be increased when it is combined with Candoxatril.Experimental, Investigational
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Candoxatril.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Mesalazine.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Candoxatril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Candoxatril.Approved, Investigational, Withdrawn
MethoserpidineCandoxatril may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of hypotension can be increased when Methyclothiazide is combined with Candoxatril.Approved
Methyl salicylateThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MethyldopaCandoxatril may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Candoxatril.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Candoxatril.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Candoxatril.Approved, Investigational
MetipranololCandoxatril may increase the hypotensive activities of Metipranolol.Approved
MetolazoneThe risk or severity of hypotension can be increased when Metolazone is combined with Candoxatril.Approved
MetoprololMetoprolol may increase the hypotensive activities of Candoxatril.Approved, Investigational
MetyrosineCandoxatril may increase the hypotensive activities of Metyrosine.Approved
MibefradilCandoxatril may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Candoxatril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Candoxatril.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Candoxatril.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Candoxatril.Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Candoxatril.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Candoxatril.Approved, Investigational
MoexiprilCandoxatril may increase the hypotensive activities of Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Candoxatril.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Candoxatril.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Candoxatril.Approved, Investigational
MuzolimineCandoxatril may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Candoxatril.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Candoxatril.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Candoxatril.Approved
NadololCandoxatril may increase the hypotensive activities of Nadolol.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Candoxatril.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Candoxatril.Approved
NaftopidilCandoxatril may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Candoxatril.Approved, Vet Approved
NebivololCandoxatril may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Candoxatril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Candoxatril.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Candoxatril.Withdrawn
NicardipineCandoxatril may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicorandilNicorandil may increase the vasodilatory activities of Candoxatril.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Candoxatril.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Candoxatril.Approved
NiguldipineCandoxatril may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineCandoxatril may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Candoxatril.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Candoxatril.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Candoxatril.Approved
NitrendipineCandoxatril may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroaspirinThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Nitroaspirin.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Candoxatril.Approved, Investigational
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Candoxatril.Approved
ObinutuzumabCandoxatril may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Candoxatril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Candoxatril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Candoxatril.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Candoxatril.Approved
OmapatrilatCandoxatril may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Candoxatril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Candoxatril.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Candoxatril.Approved
OxprenololCandoxatril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Candoxatril.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Candoxatril.Experimental, Nutraceutical
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Candoxatril.Approved
PargylinePargyline may increase the hypotensive activities of Candoxatril.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Candoxatril.Approved, Investigational
Patent BlueThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Patent Blue.Approved
PenbutololCandoxatril may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentoliniumCandoxatril may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Candoxatril.Approved, Investigational
PerindoprilCandoxatril may increase the hypotensive activities of Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Candoxatril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Candoxatril.Withdrawn
PhenoxybenzamineCandoxatril may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Candoxatril.Withdrawn
PhentolamineCandoxatril may increase the hypotensive activities of Phentolamine.Approved
Phenyl aminosalicylateThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Phenyl aminosalicylate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Candoxatril.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Candoxatril.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Candoxatril.Approved
PindololCandoxatril may increase the hypotensive activities of Pindolol.Approved, Investigational
PiretanidePiretanide may increase the hypotensive activities of Candoxatril.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Candoxatril.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Candoxatril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Candoxatril.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Candoxatril.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Candoxatril.Withdrawn
Platelet Activating FactorCandoxatril may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideThe risk or severity of hypotension can be increased when Polythiazide is combined with Candoxatril.Approved
Potassium bicarbonatePotassium bicarbonate may increase the hyperkalemic activities of Candoxatril.Approved
Potassium cationPotassium may increase the hyperkalemic activities of Candoxatril.Approved, Investigational
Potassium ChloridePotassium Chloride may increase the hyperkalemic activities of Candoxatril.Approved, Withdrawn
Potassium CitratePotassium Citrate may increase the hyperkalemic activities of Candoxatril.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Candoxatril.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Candoxatril.Approved
PregabalinThe risk or severity of angioedema can be increased when Candoxatril is combined with Pregabalin.Approved, Illicit, Investigational
ProcaineProcaine may increase the hypotensive activities of Candoxatril.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Candoxatril.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Candoxatril.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Candoxatril.Approved, Investigational
PropranololPropranolol may increase the hypotensive activities of Candoxatril.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Candoxatril.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Candoxatril.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Candoxatril.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Candoxatril.Investigational
QuinaprilCandoxatril may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinethazoneThe risk or severity of hypotension can be increased when Quinethazone is combined with Candoxatril.Approved
QuinineQuinine may increase the hypotensive activities of Candoxatril.Approved
RamiprilRamipril may increase the hypotensive activities of Candoxatril.Approved
RasagilineRasagiline may increase the hypotensive activities of Candoxatril.Approved
RemikirenRemikiren may increase the hypotensive activities of Candoxatril.Approved
RescinnamineCandoxatril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Candoxatril.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Candoxatril.Approved, Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Candoxatril.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Candoxatril.Approved
RituximabCandoxatril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Candoxatril.Approved, Investigational, Withdrawn
SacubitrilThe risk or severity of angioedema can be increased when Candoxatril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Candoxatril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Candoxatril.Approved
Salicylic acidThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Candoxatril.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Candoxatril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Candoxatril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Candoxatril.Approved
SelegilineSelegiline may increase the hypotensive activities of Candoxatril.Approved, Investigational, Vet Approved
SelexipagCandoxatril may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Candoxatril.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Candoxatril.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Candoxatril.Investigational
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Candoxatril.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Candoxatril.Approved
SirolimusThe risk or severity of angioedema can be increased when Sirolimus is combined with Candoxatril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Candoxatril.Approved, Investigational
SitaxentanCandoxatril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Candoxatril is combined with Sodium aurothiomalate.Approved, Investigational
Sodium phosphate, monobasicCandoxatril may increase the nephrotoxic activities of Sodium phosphate.Approved
SpiraprilCandoxatril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneSpironolactone may increase the hyperkalemic activities of Candoxatril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Candoxatril.Investigational
St. John's WortThe metabolism of Candoxatril can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Candoxatril.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Candoxatril.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Candoxatril.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Candoxatril.Experimental
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Candoxatril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Candoxatril.Approved, Investigational
TalinololCandoxatril may increase the hypotensive activities of Talinolol.Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Candoxatril.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Candoxatril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Candoxatril.Approved, Investigational
TemocaprilCandoxatril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Candoxatril is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Candoxatril.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Candoxatril.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Candoxatril.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Candoxatril.Approved
TerlipressinCandoxatril may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineCandoxatril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineCandoxatril may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Candoxatril.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Candoxatril.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Candoxatril.Approved
TiboloneCandoxatril may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenCandoxatril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Candoxatril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Candoxatril.Investigational
TipranavirThe serum concentration of Candoxatril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of hypotension can be increased when Tizanidine is combined with Candoxatril.Approved, Investigational
TolazolineCandoxatril may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Candoxatril.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Candoxatril.Approved
TolonidineCandoxatril may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Candoxatril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Candoxatril.Approved
TorasemideTorasemide may increase the hypotensive activities of Candoxatril.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Candoxatril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Candoxatril.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypotensive activities of Candoxatril.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Candoxatril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Candoxatril.Approved, Investigational
TriamtereneTriamterene may increase the hyperkalemic activities of Candoxatril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Candoxatril.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Candoxatril.Experimental
TrichlormethiazideThe risk or severity of hypotension can be increased when Trichlormethiazide is combined with Candoxatril.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Candoxatril.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Candoxatril.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Candoxatril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Candoxatril.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Candoxatril.Investigational
Trolamine salicylateThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Trolamine salicylate.Approved
UdenafilUdenafil may increase the antihypertensive activities of Candoxatril.Approved, Investigational
UnoprostoneCandoxatril may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Candoxatril.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Candoxatril.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Candoxatril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Candoxatril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Candoxatril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Candoxatril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Candoxatril.Approved, Investigational
VincamineCandoxatril may increase the hypotensive activities of Vincamine.Experimental
VinpocetineCandoxatril may increase the hypotensive activities of Vinpocetine.Investigational
XipamideCandoxatril may increase the hypotensive activities of Xipamide.Experimental
XylometazolineCandoxatril may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Candoxatril.Approved, Investigational, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Candoxatril.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Candoxatril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Candoxatril.Approved, Investigational, Withdrawn
ZofenoprilCandoxatril may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Candoxatril.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0014754
KEGG Drug
D01070
PubChem Compound
5362417
PubChem Substance
46509011
ChemSpider
16736409
BindingDB
50084625
ChEBI
3353
ChEMBL
CHEMBL35084
Therapeutic Targets Database
DAP001145
PharmGKB
PA164764517
Wikipedia
Candoxatril

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP3.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00225 mg/mLALOGPS
logP3.55ALOGPS
logP4.68ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)4.29ChemAxon
pKa (Strongest Basic)1.32ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area111.16 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity138.16 m3·mol-1ChemAxon
Polarizability57.2 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9142
Blood Brain Barrier+0.8437
Caco-2 permeable-0.6787
P-glycoprotein substrateSubstrate0.8158
P-glycoprotein inhibitor INon-inhibitor0.8213
P-glycoprotein inhibitor IINon-inhibitor0.9075
Renal organic cation transporterNon-inhibitor0.7707
CYP450 2C9 substrateNon-substrate0.7497
CYP450 2D6 substrateNon-substrate0.7492
CYP450 3A4 substrateSubstrate0.6952
CYP450 1A2 substrateNon-inhibitor0.7035
CYP450 2C9 inhibitorNon-inhibitor0.7548
CYP450 2D6 inhibitorNon-inhibitor0.8484
CYP450 2C19 inhibitorNon-inhibitor0.6641
CYP450 3A4 inhibitorNon-inhibitor0.9144
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8421
Ames testNon AMES toxic0.62
CarcinogenicityNon-carcinogens0.9494
BiodegradationNot ready biodegradable0.8614
Rat acute toxicity2.5001 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9833
hERG inhibition (predictor II)Non-inhibitor0.5652
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as indanes. These are compounds containing an indane moiety, which consists of a cyclopentane fused to a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Indanes
Sub Class
Not Available
Direct Parent
Indanes
Alternative Parents
Fatty acid esters / Fatty amides / Dicarboxylic acids and derivatives / Secondary carboxylic acid amides / Carboxylic acid esters / Dialkyl ethers / Carboxylic acids / Organopnictogen compounds / Organonitrogen compounds / Organic oxides
show 2 more
Substituents
Indane / Fatty acid ester / Dicarboxylic acid or derivatives / Fatty amide / Fatty acyl / Carboxamide group / Secondary carboxylic acid amide / Carboxylic acid ester / Ether / Dialkyl ether
show 11 more
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
dicarboxylic acid monoester, monocarboxylic acid, monocarboxylic acid amide (CHEBI:3353)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Thermolysin-like specificity, but is almost confined on acting on polypeptides of up to 30 amino acids (PubMed:15283675, PubMed:8168535). Biologically important in the destruction of opioid peptide...
Gene Name
MME
Uniprot ID
P08473
Uniprot Name
Neprilysin
Molecular Weight
85513.225 Da
References
  1. O'Connell JE, Jardine AG, Davidson G, Connell JM: Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens. 1992 Mar;10(3):271-7. [PubMed:1315825]
  2. Elsner D, Muntze A, Kromer EP, Riegger GA: Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol. 1992 Aug 15;70(4):494-8. [PubMed:1386491]
  3. Plamboeck A, Holst JJ, Carr RD, Deacon CF: Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia. 2005 Sep;48(9):1882-90. Epub 2005 Jul 16. [PubMed:16025254]
  4. Sansoe G, Aragno M, Mastrocola R, Cutrin JC, Silvano S, Mengozzi G, Smedile A, Rosina F, Danni O, Rizzetto M: Overexpression of kidney neutral endopeptidase (EC 3.4.24.11) and renal function in experimental cirrhosis. Am J Physiol Renal Physiol. 2006 Jun;290(6):F1337-43. Epub 2006 Jan 31. [PubMed:16449355]
  5. Hirata Y, Suzuki E, Hayakawa H, Matsuoka H, Sugimoto T, Kangawa K, Matsuo H: Mechanisms of the natriuretic effects of neutral endopeptidase inhibition in Dahl salt-sensitive and salt-resistant rats. J Cardiovasc Pharmacol. 1994 Feb;23(2):283-90. [PubMed:7511759]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Dumoulin MJ, Adam A, Rouleau JL, Lamontagne D: Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed. J Cardiovasc Pharmacol. 2001 Apr;37(4):359-66. [PubMed:11300648]
  2. Kostova E, Jovanoska E, Zafirov D, Jakovski K, Maleska V, Slaninka-Miceska M: Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats. Bratisl Lek Listy. 2005;106(12):407-11. [PubMed:16642666]

Drug created on June 13, 2005 07:24 / Updated on July 02, 2018 17:21